Aurealis Therapeutics team visited China from June 9–13, 2025, for a dedicated partnering week. Juha Yrjänheikki (CEO), Laurent Décory (COO), Hanna-Riikka Kärkkäinen (Director, Quality & Regulatory Affairs), and Jere Kurkipuro (Director, Pre-clinical & Pharmacology) met with investors, scientific partners, and licensing stakeholders to explore new collaboration opportunities.
World Drug Safety Congress Europe 2025
Aurealis Therapeutics Drug Safety Officer, Matleena Piiroinen, attended the World Drug Safety Congress Europe 2025, that took place 7–8 October in Amsterdam, The Netherlands. As Europe’s leading forum for drug safety and pharmacovigilance, the congress provides an important platform to exchange knowledge and address the most pressing challenges faced by safety professionals. At Aurealis Therapeutics, patient safety is central to